Ghaith Abdul Karim, Yang Xinlan, Khalilullah Taha, Tang Linda, Radwan Hasan, Weinberg Joshua, Khalifeh Jawad, Ahmed A Karim, Azad Tej, Foster Chase, Theodore Nicholas, Redmond Kristin J, Lubelski Daniel
Department of Neurosurgery, Johns Hopkins University, School of Medicine, 600 N. Wolfe Street/Meyer 5-181, Baltimore, MD, 21287, USA.
School of Medicine, Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
J Neurooncol. 2025 Jun 25. doi: 10.1007/s11060-025-05104-y.
This study aims to provide a national-level insight into the optimal management of spinal chordoma, a type of rare and complicated malignancy, and to identify effective radiation therapy (RT) strategies for patients with spinal chordoma by comparing photon versus proton therapies.
Patients with histologically confirmed spinal chordoma were identified from the NCDB. Patients' demographics, disease characteristics and treatments were compared between the radiation and no-radiation groups. Kaplan-Meier assessed 10-year overall survival (OS). Multivariate Cox regression and machine learning models-Random Survival Forest and Gradient Boosting-identified predictive factors and thresholds of tumor size for mortality risk, with SHAP used to quantify predictor importance.
Of 1204 patients, 495 (41.1%) received RT; 73.9% received photons and 26.1% protons. GTR significantly improved OS compared to STR (p < 0.0001). RT was associated with reduced short-term morality at 90-days (p = 0.025) and 1-year (p = 0.016). Proton therapy showed superior 10-year OS compared to photon therapy (p = 0.019). Beam technology, BED dose, sequence, and reirradiation had minimal impact on OS. Cox regression identified age (HR = 1.03, p < 0.001), STR (HR = 1.42, p = 0.005), and proton therapy (HR = 0.58, p = 0.044) as independent mortality predictors. Machine learning identified tumor size thresholds (photons: 83 mm; protons: 70 mm) and ranked age, tumor size, and EOR as top survival predictors.
Aggressive surgical resection (GTR) remains the primary treatment for spinal chordoma. Proton therapy that allows for dose escalation provided 10-year survival benefits compared to photon therapy. Age, tumor size and EOR are important factors in predicting 10-year mortality risk.
本研究旨在对脊柱脊索瘤(一种罕见且复杂的恶性肿瘤)的最佳管理提供国家级的见解,并通过比较光子疗法与质子疗法,为脊柱脊索瘤患者确定有效的放射治疗(RT)策略。
从国家癌症数据库(NCDB)中识别出组织学确诊的脊柱脊索瘤患者。比较放疗组和非放疗组患者的人口统计学、疾病特征和治疗情况。采用Kaplan-Meier法评估10年总生存率(OS)。多变量Cox回归以及机器学习模型——随机生存森林和梯度提升法——确定了死亡风险的预测因素和肿瘤大小阈值,使用SHAP来量化预测因素的重要性。
在1204例患者中,495例(41.1%)接受了放疗;73.9%接受光子治疗,26.1%接受质子治疗。与次全切除(STR)相比,全切除(GTR)显著改善了总生存率(p<0.0001)。放疗与90天(p = 0.025)和1年(p = 0.016)时短期死亡率降低相关。与光子治疗相比,质子治疗显示出更好的10年总生存率(p = 0.019)。射束技术、生物等效剂量(BED)、照射顺序和再程放疗对总生存率的影响最小。Cox回归确定年龄(HR = 1.03,p<0.001)、次全切除(HR = 1.42,p = 0.005)和质子治疗(HR = 0.58,p = 0.044)为独立的死亡预测因素。机器学习确定了肿瘤大小阈值(光子治疗:83毫米;质子治疗:70毫米),并将年龄、肿瘤大小和切除范围(EOR)列为主要的生存预测因素。
积极的手术切除(全切除)仍然是脊柱脊索瘤的主要治疗方法。与光子治疗相比,允许剂量递增的质子治疗具有10年生存获益。年龄、肿瘤大小和切除范围是预测10年死亡风险的重要因素。